Key result
Warfarin prevents 64% of strokes in patients with atrial fibrillation but is underprescribed, highlighting the need for new oral anticoagulants like dabigatran etexilate.
Why the study?
Does dabigatran etexilate improve stroke prevention compared to warfarin in patients with atrial fibrillation?
Does dabigatran etexilate improve stroke prevention compared to warfarin in patients with atrial fibrillation?
This editorial discusses the need for new oral anticoagulants like dabigatran etexilate due to the limitations and suboptimal real-world effectiveness of warfarin in patients with atrial fibrillation.
In patients with atrial fibrillation, warfarin prevents 64% of strokes.1 Thus, warfarin has become the recommended treatment for candidates for anticoagulation therapy who have atrial fibrillation and at least one additional risk factor for stroke.2 Despite clear and consistent recommendations,3 warfarin is prescribed to only two thirds of appropriate candidates.4 Several factors contribute to suboptimal use of warfarin therapy: drug and dietary interactions, inconvenience of monitoring the international normalized ratio (INR), risk of hemorrhage, and concerns about real-world effectiveness, which averages 35%.4 Thus, new oral anticoagulants are needed.Dabigatran etexilate, an oral thrombin inhibitor, appears to be an anticoagulant that . . .
No takes yet. Share an insight, caveat, or question.
Brian F. Gage (2009) conducted an editorial in atrial fibrillation. Dabigatran etexilate vs. warfarin was evaluated. Warfarin prevents 64% of strokes in patients with atrial fibrillation but is underprescribed, highlighting the need for new oral anticoagulants like dabigatran etexilate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: